EVENTS | VIEW CALENDAR
LI-COR now offers contract manufacturing for early-phase cGMP materials
LINCOLN, Neb.—Building on its expertise in reagent and dye production, LI-COR is expanding its services to include synthesis and conjugation services for early-phase cGMP production, the company reported in late August.
“We offer a variety of custom services and can apply our unique expertise in dye and probe development for intra-operative surgery to help researchers,” says Bambi Reynolds, senior business development manager. “We have expanded our production facility to accommodate contract manufacturing for both preclinical and early-phase clinical applications.”
LI-COR offers development and manufacturing of dyes and small molecules, including custom derivatives of fluorescent dyes and active pharmaceutical ingredients.
“Our clients in need of dye-conjugated biomolecules are able to benefit from our extensive experience in biology and chemistry services that we have developed for our instrumentation platforms,” said Reynolds.
LI-COR touts itself as a pioneer in the use of near-infrared (NIR) technology as a detection method. In the early 1990s LI-COR introduced NIR DNA sequencing technology that has led to other preclinical applications including protein and small animal imaging using NIR. This preclinical development has led to two near-infrared dyes being translated into the clinical trials using targeted NIR as a method for both detection and treatment of various types of cancer.